
Academic Journal
Q1Expert Review of Clinical Pharmacology
About Expert Review of Clinical Pharmacology
About Expert Review of Clinical Pharmacology
Expert Review of Clinical Pharmacology is a peer-reviewed scholarly journal published by Taylor and Francis Ltd. (United Kingdom). It focuses on Q1. Publication coverage spans 2008-2026.
Key indicators: ISSN 1751-2433, 1751-2441; H-index 73.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (73): Strong citation impact — 73 articles cited at least 73 times each, reflecting solid influence.
Publishing in Expert Review of Clinical Pharmacology
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Expert Review of Clinical Pharmacology?
1751-2433, 1751-2441.
Who publishes Expert Review of Clinical Pharmacology?
Taylor and Francis Ltd..
What are Expert Review of Clinical Pharmacology's metrics?
H-index 73.
Is Expert Review of Clinical Pharmacology peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Diabetes Treatment and Management; Health Systems, Economic Evaluations, Quality of Life; Pharmaceutical studies and practices; Pharmacogenetics and Drug Metabolism; Pharmacological Effects and Toxicity Studies; Pharmaceutical Practices and Patient Outcomes.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Efficacy of minocycline-containing bismuth quadruple therapy for Helicobacter pylori infection: a single-center retrospective study
Xiaomin Wang, Liyan Dong, Guo Lin, Zhixin Jiang et al.
2026-10-13 · DOI: 10.1080/17512433.2026.2749579Pentosan polysulfate sodium and retinal safety: reconciling conflicting evidence and defining a pragmatic clinical pharmacology framework
Shwetambari Ingawale, Hira Bakhtiar Khan, Mehwash Nadeem
2026-10-12 · DOI: 10.1080/17512433.2026.2747637Emerging pharmacological therapies for bronchiectasis
Meghan Marmor, Mark Metersky
2026-10-09 · DOI: 10.1080/17512433.2026.2744253Limitations of current neuroprotective therapies in dementia with Lewy bodies
Deirdre M. O’shea, Shanell Disla, Alyssa E. Gosling, German A. Valdelamar et al.
2026-10-08 · DOI: 10.1080/17512433.2026.2742316Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group
Concetta Calabrò, Francesco Ciccimarra, Anna Milella, Gerardo Cazzato et al.
2026-10-07 · DOI: 10.1080/17512433.2026.2744573Off-label drug use in children: prevalence, risks, and regulation
Antje Neubert, Sonja Eberl
2026-10-03 · DOI: 10.1080/17512433.2026.2742318Brensocatib in non-cystic fibrosis bronchiectasis: neutrophil serine protease modulation, clinical evidence, and therapeutic positioning
Muhammad Saeed Akhtar
2026-10-03 · DOI: 10.1080/17512433.2026.2739561Drug safety and pregnancy: more evidence or changing mindset?
Alain Braillon
2026-10-03 · DOI: 10.1080/17512433.2026.2738821Authors’ reply: evidential standards, levels of inference, and shared objectives
Adrienne Y. L. Chan, Ian C. K. Wong, Kenneth K. C. Man
2026-10-03 · DOI: 10.1080/17512433.2026.2739122Non-antibiotic therapeutic approaches for antimicrobial resistance: current evidence and future directions
Bharath Kumar Ganesan, Archana Mishra, Debasish Hota, Rituparna Maiti et al.
2026-10-03 · DOI: 10.1080/17512433.2026.2739560Beyond genotype: dynamic metabolic phenotyping for safer clozapine prescribing in Asian populations
Takahiko Nagamine
2026-10-03 · DOI: 10.1080/17512433.2026.2739558AI-enabled digital therapeutics in pharmacy practice: prescription software, medication optimization, safety surveillance, and future clinical positioning
Wajid Zaman, Asma Ayaz
2026-10-03 · DOI: 10.1080/17512433.2026.2739562Preventing psoriatic arthritis: is disease interception the next frontier in clinical pharmacology?
Nikolaos Kougkas, George Fragoulis
2026-10-03 · DOI: 10.1080/17512433.2026.2737173CYP2C19 genotype-guided P2Y12 inhibitor therapy optimization in patients at high bleeding risk: existing evidence and future directions
Ngoc Phuong Mai Le, Angela Su, Kevin A. Friede, Craig R. Lee et al.
2026-09-02 · DOI: 10.1080/17512433.2026.2733754Could tumor necrosis factor inhibitor therapy reduce the incidence of depression among patients with ankylosing spondylitis?
Oh Chan Kwon
2026-09-02 · DOI: 10.1080/17512433.2026.2733760Theranostics in the management of prostate cancer: from concept to clinical practice
Kannan Sridharan, Teresa Alonso-Gordoa, Gowri Sivaramakrishnan, Javier Molina Cerrillo et al.
2026-09-02 · DOI: 10.1080/17512433.2026.2737765Efficacy and safety of medications for managing urinary incontinence in people living with cognitive impairment, dementia, or in long-term care: a systematic review
Anne Nileshni Fernando, Joan Ostaszkiewicz, J Simon Bell, Cindy Bakhoya Mbingi et al.
2026-09-02 · DOI: 10.1080/17512433.2026.2729008Modifying the course and altering the natural history of Crohn’s disease
Beatriz Gros, Lauranne A. A. P. Derikx, Marie Truyens, Nathan Grellier et al.
2026-09-02 · DOI: 10.1080/17512433.2026.2737182Keeping the weight off: can oral orforglipron maintain all the weight loss following glucagon-like peptide-1 receptor agonist (GLP-1 RA) discontinuation?
Abdulhameed Alhazmi, Carel W. le Roux
2026-09-02 · DOI: 10.1080/17512433.2026.2731087The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis
Albina Tyker, Naoyuki Kuse, Barak Pertzov, Martin RJ Kolb et al.
2026-09-02 · DOI: 10.1080/17512433.2026.2737175Reviews
Community Reviews
Version History
October 9, 2026 at 10:02 pm
October 2, 2026